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Significance of the Study
• Rare variants within exon 2 of the TREM2 gene increase the risk of Alzheimer’s disease in Caucasian 
populations. This is the first case-control study to assess the association between these variants and the 
risk of Alzheimer’s disease in a North African population. We sequenced exon 2 of the TREM2 gene 
in a cohort of Tunisian patients with late-onset Alzheimer’s disease and healthy individuals and iden-
tified 5 variants, none of which was associated with the risk of Alzheimer’s disease. Our study does not 
support a major role for TREM2 in the pathogenesis of late-onset Alzheimer’s disease in the Tunisian 
population.
DOI: 10.1159/000489779
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Abstract
Objective: Rare variants in the TREM2 gene have been re-
ported to significantly increase the risk of Alzheimer’s dis-
ease in Caucasian populations. Hitherto, this association was 
not studied in North African populations. In this work, we 
aimed to study the association between TREM2 exon 2 vari-
ants and the risk of late-onset Alzheimer’s disease (LOAD) in 
a Tunisian population. Subjects and Methods: We se-
quenced exon 2 of TREM2 in a Tunisian cohort of 172 LOAD 
patients and 158 control subjects. We used the Fisher exact 
test to compare the distribution of allelic frequencies be-
tween the two groups. Results: We identified 4 previously 
reported nonsynonymous variants (p.Asp39Glu, p.Arg62His, 
p.Thr96Lys, and p.Val126Gly) and 1 novel synonymous vari-
ant (p.Gln109Gln), none of which was significantly associat-
ed with the risk of Alzheimer’s disease. Moreover, the rare 
TREM2 variant (p.Arg47His), which was considered to be a 
risk factor for Alzheimer’s disease in European descent pop-
ulations, was not detected in our cohort. Conclusion: These 
findings do not support a major role for TREM2 in the patho-
genesis of LOAD in the Tunisian population.
© 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
TREM2 gene encodes the triggering receptor expressed 
on myeloid cells 2, which is highly expressed in microglia 
of the central nervous system [1] and is involved in regu-
lating the immune system by promoting phagocytosis 
This is an Open Access article licensed under the Creative Commons 
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and regulating the inflammatory response. The rare mis-
sense mutation p.Arg47His (rs75932628) within TREM2 
increases the risk of neurodegenerative disorders such as 
Parkinson’s disease [2], essential tremor [3], and late-on-
set Alzheimer’s disease (LOAD). This mutation was iden-
tified as a rare risk factor for LOAD in several European 
descent cohorts with an odds ratio similar to that for apo-
lipoprotein E epsilon 4 (ApoE ε4) [4, 5].
TREM2 variants associated with Alzheimer’s disease 
(AD) have been screened in various populations world-
wide; however, no studies have been carried-out in North 
African populations. Most of the aforementioned vari-
ants were observed in exon 2 of the TREM2 gene. There-
fore, the aim of this work was to evaluate the association 
of TREM2 exon 2 variants with risk of AD in a sample of 
the Tunisian population.
Subjects and Methods
Subjects
One hundred seventy-two Tunisian patients with LOAD were 
recruited from the Neurology Department of Razi Hospital, Ma-
nouba, Tunisia. Clinical diagnosis of LOAD was done according to 
the criteria of the National Institute of Neurological and Communi-
cation Disorders and Stroke-Alzheimer’s Disease and Related Dis-
orders Association (NINCDS-ADRDA) [6]. In addition, 158 unre-
lated control subjects were recruited from different primary care 
clinics. None of the control group subjects had cognitive impair-
ment or personal or familial history of neurological and psychiatric 
disorders. Written informed consent was obtained from each indi-
vidual prior to enrollment in the genetic study. Research protocols 
were approved by the Medical Ethics Committee of Razi Hospital 
and conformed to the guidelines of the Declaration of Helsinki.
ApoE Genotyping and TREM2 Sequencing
Blood samples were collected from LOAD patients and con-
trols. Genomic DNA was extracted from blood by the salting-out 
method [7]. ApoE genotyping was performed as previously de-
scribed [8]. Exon 2 of TREM2 gene was amplified by polymerase 
chain reaction (PCR) from genomic DNA using two primers: 
5′-TGAATGAATGTCTCCTCCCCAG-3′ and 5′-CAGCCACT-
GCCCACTCA-3′, under the following reaction conditions: dena-
turation at 95  ° C for 5 min followed by 30 cycles of 95  ° C for 30 s, 
60  ° C for 30 s, and 72  ° C for 30 s, and a final cycle of 7-min exten-
sion at 72  ° C. PCR products were purified and sequenced using the 
BigDye Terminator Cycle Sequencing Kit v1.1 on a 3,500xl Ge-
netic Analyzer DNA sequencer (Applied Biosystems, Foster City, 
CA, USA). Sequences were analyzed using the SeqScape software 
(Applied Biosystems) and compared to the TREM2 GenBank ref-
erence sequence (NM_018965).
In silico Tools
The impact of TREM2 variations was predicted using SIFT 
(Sorting Intolerant From Tolerant; http://sift.jcvi.org/www/SIFT_
chr_coords_submit.html), PolyPhen-2 (Polymorphism Pheno-
typing v2; http://genetics.bwh.harvard.edu/pph2/) and Pre-
dictSNP2 (http://loschmidt.chemi.muni.cz/predictsnp2/) [9]. Fre-
quencies of variants were reported from exome database (1,000G; 
http://browser.1000genomes.org/index.html), ExAC (http://exac.
broadinstitute.org/), EVS (http://evs.gs.washington.edu/EVS/), 
and Great Middle East (GME) Variome Project database (http://
igm.ucsd.edu/gme/data-browser.php) including 508 samples 
from North Africa.
Statistical Analysis
We used Fisher’s exact test to compare the distribution of al-
lelic frequencies between LOAD patients and control groups. 
ApoE genotype and sex distributions were compared using the χ2 
test and mean age was compared using the t test. All analyses were 
two-tailed and a p value of 0.05 or less was considered statistically 
significant. Odds ratios and 95% confidence intervals were calcu-
lated using SPSS.
Results
Demographic characteristics and ApoE genotypes of 
Tunisian LOAD patients (n = 172) and controls (n = 158) 
are summarized in Table 1. Both groups had similar sex 
ratios and similar mean ages. ApoE genotyping showed a 
Table 1. Demographic characteristics of subjects
LOAD patients Controls p value
Subjects, n 172 158
Sex ratio (male:female) 0.5 (58:114) 0.64 (62:96) 0.297
Mean age at examination ± SD, years 75.84±9.64 74.27±4.17 0.06
Mean age at onset ± SD, years 68.69±10.05
ApoE ε4/ApoE ε4, n (%) 27 (15.7) 3 (1.9) 1.3 10e-5
ApoE ε3/ApoE ε4, n (%) 73 (42.4) 45 (28.5) 0.008
ApoE ε3/ApoE ε3, n (%) 72 (41.9) 110 (69.6) 0.03
LOAD, late-onset Alzheimer’s disease; SD, standard deviation.
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significant difference in genotype distributions between 
the two groups; as expected, the ApoE ε4 allele was over-
represented in LOAD patients compared to the control 
group (36.9 vs. 16.1%; p < 0.05). The ApoE ε2 allele was 
not detected in patients and controls.
Sequencing of exon 2 of the TREM2 gene revealed 5 
variants in 14 LOAD patients and 1 variant in 5 controls. 
As shown in Table 2, 4 previously reported nonsynony-
mous variants (p.Asp39Glu, p.Arg62His, p.Thr96Lys, 
and p.Val126Gly) and 1 novel synonymous variant (p.
Gln109Gln) were observed in patients. The variant p.
Thr96Lys was also identified in controls. All variants were 
present in the heterozygous state and were detected in 
separate individuals (no individuals carried 2 or more 
variants). Among the 14 patients carrying the TREM2 
variants, 11 had a positive family history of AD (Table 3).
The frequencies of each variation in the population’s 
exome sequencing database are detailed in Table 2. No 
common variants having minor allele frequency (MAF) 
> 5% were found, and 2 variants (p.Val126Gly and p.Asp-
39Glu) were rare, with MAF < 1%. Three variants were 
predicted to have a probable damaging effect (p.Asp39G-
lu, p.Thr96Lys, and p.Val126Gly; Table 4). The associa-
tion analysis of all the identified TREM2 variants and AD 
Table 2. Variants of TREM2 after sequencing of exon 2 in LOAD patients and controls
Variant db SNP ID Position 
(GRCh37)
Exonic
function
LOAD patients
(carriers, 
MAF)
Controls
(carriers, 
MAF)
p
value
OR
(95% CI)
Population frequency data
1,000G gnomAD EVS GME
p.Asp39Glu rs200392967 g.41129275G>C nonsyn 1 (0.005) 0 1 NA 0 6.5 e-5 7.6 e-5 0
p.Arg62His rs143332484 g.41129207C>T nonsyn 2 (0.011) 0 0.49 NA 0.005 0.008 0.007 0
p.Thr96Lys rs2234253 g.41129105G>T nonsyn 5 (0.029) 6 (0.037) 0.76 1.3
(0.39-4.36)
0.041 0.012 0.039 0
p.Gln109Gln NA g.41129065C>T syn 5 (0.029) 0 0.06 NA
p.Val126Gly rs121908402 g.41129015A>C nonsyn 1 (0.005) 0 1 NA 0 8.2 e-6 0 0
LOAD, late-onset Alzheimer’s disease; db SNP, single nucleotide polymorphism database; MAF, minor allele frequency; syn, synonymous; nonsym, 
nonsynonymous.
Table 3. Characteristics of individuals carrying the TREM2 variants
Variant Carrier Gender Age at examination/
Age at onset,
years
ApoE
genotype
Family history of
neurodegenerative 
disease
p.Asp39Glu patient 1 F 86/82 ε4/ε4 yes
p.Arg62His patient 2 M 79/71 ε3/ε3 yes
patient 3 F 78/71 ε3/ε3 yes
p.Thr96Lys patient 4 M 79/66 ε4/ε4 yes
patient 5 M 69/67 ε3/ε3 yes
patient 6 F 72/65 ε3/ε4 yes
patient 7 F 80/75 ε3/ε4 yes
patient 8 F 89/79 ε3/ε3 yes
control 1 M 71/– ε3/ε3 no
control 2 M 68/– ε3/ε4 no
control 3 F 70/– ε3/ε3 no
control 4 M 68/– ε3/ε3 no
control 5 F 70/– ε3/ε4 no
p.Gln109Gln patient 9 M 85/70 ε3/ε4 yes
patient 10 F 75/65 ε4/ε4 yes
patient 11 F 72/67 ε3/ε3 no
patient 12 F 85/68 ε3/ε4 no
patient 13 F 77/72 ε3/ε3 no
p.Val126Gly patient 14 M 82/72 ε3/ε4 yes
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was not statistically significant (Table 2). Even the rare 
variants p.Val126Gly and p.Asp39Glu were not signifi-
cantly associated with AD (p > 0.05).
Discussion
This is the first investigation into the possible associa-
tion between TREM2 variants and risk of AD in a North 
African population. In this study, we sequenced exon 2 of 
the TREM2 gene in a cohort of Tunisian patients with 
LOAD and healthy individuals, and identified 5 variants 
(p.Asp39Glu, p.Arg62His, p.Thr96Lys, p.Gln109Gln, 
and p.Val126Gly). The p.Arg47His mutation was not 
found in our cohort. Association analysis revealed that 
none of the identified variants were associated with AD 
risk. Therefore, we could not test the interaction of the 
ApoE ε4 allele with these variants.
A summary of the reported screening studies for 
TREM2 mutations to date, including AD patients, is pre-
sented in Table 5. TREM2 p.Arg62His was previously ob-
served in AD patients and controls in Spanish, Belgian, 
Table 4. In silico prediction of TREM2 missense variants
Variant db SNP ID Position (GRCh37) SIFT Polyphen2 PredictSNP2
p.Asp39Glu rs200392967 g.41129275G>C tolerated possibly damaging deleterious
p.Arg62His rs143332484 g.41129207C>T tolerated benign neutral
p.Thr96Lys rs2234253 g.41129105G>T damaging probably damaging neutral
p.Val126Gly rs121908402 g.41129015A>C damaging Probably damaging deleterious
Table 5. Summary of all variant screening studies of TREM2 in patients with Alzheimer’s disease (AD)
Ethnicity AD patients TREM2 variants in AD patients
exon 2 exon 3 exon 4
Caucasian 256 European + 836 North 
American [5]
Q33X, Y38C, R47H, R62H, T66M, D87N, 
T96K, R98W
R136Q, H157Y –
117 Norwegian + 944 Dutch + 
517 German + 3,759 Icelandic + 
399 US [4]
R47H – –
726 French [13] Q33X, R47H, R62H, R62C, D87N, T96K – –
427 American [14] R47H – –
504 Spanish [15] R47H, R62H – –
3,172 Spanish [16] R47H – –
1,216 Belgian [11] D39G, D39E, R47H, G58A, R62H, D87N, 
T96K
L133L, H157Y S162R, L211P, 
T223I
2,082 US [10] Q33X,R47H, R52H, R62H, T66M, D87N, 
T96K
R136W, R136Q, 
H157Y
W191X, E202D, 
L211P, H215Q, 
T223I
210 North American [17] R47H, D87N, H157Y L205P, G219C
East Asian 1,133 Chinese [18] V34V, C110C, H114H, G115S – –
360 Chinese [19] A130V – –
988 Chinese [20] - H157Y S183C, A192T
400 Korean [21] - H157Y A192T
2,190 Japanese [22] R47H, H157Y L211P
AfricanAmeri-
can
899 African American [23] R47H, R62H, D87N E151K, W191X, L211P
Others 131 Iranian [24] R47H, G55R, R62H, R62C – –
Variations significantly associated with AD are underlined.
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and French populations (Table 5), and did not show a 
nominally significant association with AD. However, a 
previous case-control study of large European American 
descent cohorts showed that in addition to p.Arg47His 
[10], p.Arg62His is a risk factor for AD. The variant 
rs2234253 (p.Thr96Lys), detected in Belgian, French, and 
Japanese populations (Table 5), was not shown to en-
hance AD risk. In our study, p.Thr96Lys was the unique 
variant detected in controls and LOAD patients with 
equivalent MAF. According to public exome databases, 
this variant was more common in African populations 
(MAF = 14.5%, 1,000G) than other populations, but was 
not present in North African populations of the GME 
(Table 2).
Two rare variants predicted to be deleterious, p.Asp-
39Glu and p.Val126Gly, were identified in our study. The 
p.Asp39Glu was previously reported in 2 AD patients at 
the heterozygous state [11], while homozygous p.Val-
126Gly was reported in 2 patients with Nasu-Hakola dis-
ease [12]. Among the 5 variants, variant Gln109Gln was 
not found in any of the exome databases. However, this 
variant is synonymous and does not change the amino 
acid sequence of TREM2 protein.
The previously reported rare variant rs75932628 (p.
Arg47His), identified to be a risk factor for AD in Cauca-
sian populations (Table 5), was not found in our cohort. 
Our findings are in agreement with published reports of 
African American, Iranian, and East Asian populations 
(Table 5) which showed that the p.Arg47His mutation 
could not be linked to an increased risk of AD. In our 
study, the lack of association of the p.Arg47His variant 
may be due to its very low MAF in the Tunisian popula-
tion. In the GME database, this genetic polymorphism 
had a global MAF of 0.15 and 0.1% in North African pop-
ulations. Moreover, this variant is considered to be a risk 
factor according to the ethnicity of the population. AD 
risk in the Tunisian population may be influenced by ge-
netic and/or environmental factors which might reduce 
the effect of this variant. However, the limitation of our 
work is the small cohort size, which could explain the lack 
of statistical significance.
Conclusion
This study is the first to explore the possibility of an 
association of TREM2 with the risk of AD in North Af-
rica, particularly in Tunisia. This population seems to be 
closer to the African American or East Asian populations 
than to the European ones regarding the AD risk factor 
p.Arg47His. We hypothesize that variations in exon 2 of 
TREM2 may not play a major role in the pathogenesis of 
LOAD in the Tunisian population. However, further 
studies on larger cohorts of North African populations 
are needed to confirm this hypothesis.
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